These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36403884)

  • 1. Small biotechs versus large pharma: Who drives first-in-class innovation in oncology?
    Kennedy KH; Gomez K; Thovmasian NJ; Chang DC
    Drug Discov Today; 2023 Feb; 28(2):103456. PubMed ID: 36403884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharma Success in Product Development—Does Biotechnology Change the Paradigm in Product Development and Attrition.
    Evens RP
    AAPS J; 2016 Jan; 18(1):281-5. PubMed ID: 26475480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
    Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
    PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of external innovation on new drug approvals: A retrospective analysis.
    Liu X; Thomas CE; Felder CC
    Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
    Tay-Teo K; Ilbawi A; Hill SR
    JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Origin of First-in-Class Drugs: Innovation Versus Clinical Benefit.
    Osipenko L; Potey P; Perez B; Angelov F; Parvanova I; Ul-Hasan S; Mossialos E
    Clin Pharmacol Ther; 2024 Feb; 115(2):342-348. PubMed ID: 37983965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotechs follow big pharma lead back into academia.
    Kling J
    Nat Biotechnol; 2011 Jul; 29(7):555-6. PubMed ID: 21747364
    [No Abstract]   [Full Text] [Related]  

  • 11. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
    Chung TD
    Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2016 in review: FDA approvals of new molecular entities.
    Griesenauer RH; Kinch MS
    Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming the obstacles in the pharma/biotech industry: 2009 update.
    Graul AI; Revel L; Tell M; Rosa E; Cruces E
    Drug News Perspect; 2010; 23(1):48-63. PubMed ID: 20155219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Swiss Startup Framework: A Highly Effective Network Supporting the Generation of Emerging Biotech Businesses.
    Mitchell I; Steiner S; Altorfer M; Suter-Dick L
    Chimia (Aarau); 2020 Oct; 74(10):765-767. PubMed ID: 33115556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The year's new drugs & biologics 2015: Part I.
    Graul AI; Cruces E; Stringer M
    Drugs Today (Barc); 2016 Jan; 52(1):41-89. PubMed ID: 26937494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming further challenges in the pharma/biotech industry: 2007 update.
    Graul AI; Cruces E; Revel L; Serradell N; Rosa E
    Drug News Perspect; 2008; 21(1):44-58. PubMed ID: 18301809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise of micropharma.
    Barden CJ; Weaver DF
    Drug Discov Today; 2010 Feb; 15(3-4):84-7. PubMed ID: 19837185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unveiling the impacts of FDA Breakthrough Therapy Designation: a dual-perspective examination of economic and developmental outcomes for biotechnology companies.
    Williamson J; Spicer AJ; Louramo E; Jalkanen J
    Drug Discov Today; 2024 Apr; 29(4):103919. PubMed ID: 38365000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.